Geração de células T para CAR adoptivo Therapy no Contexto do Glioblastoma Padrão de Atendimento
February 16th, 2015
•Katherine Riccione1,2, Carter M. Suryadevara1,3, David Snyder1, Xiuyu Cui1, John H. Sampson1,2,3, Luis Sanchez-Perez1
1Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University, 2Department of Biomedical Engineering, Duke University, 3Department of Pathology, Duke University
The lymphodepletive and immunomodulatory effects of chemotherapy and radiation standard of care can be leveraged to enhance the antitumor efficacy of T cell immunotherapy. We outline a method for generating EGFRvIII-specific chimeric antigen receptor (CAR) T cells and administering them in the context of glioblastoma standard of care.
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved